8-K: AbbVie Reports Mixed Q1 Results, Raises Full-Year EPS Guidance Amidst Leadership Transition

AbbVie's first-quarter results show a mixed performance with increased revenue and GAAP EPS, but a decrease in adjusted EPS, alongside a leadership transition and raised full-year guidance.

Summary

• AbbVie reported first-quarter 2024 net revenues of $12.310 billion, a 0.7% increase on a reported basis and 1.6% on an operational basis.
• The company's GAAP diluted earnings per share (EPS) was $0.77, a significant increase of 492.3%, while adjusted diluted EPS was $2.31, a decrease of 6.1%.
• These results include an unfavorable impact of $0.08 per share related to acquired IPR&D and milestones expense.
• Global net revenues from the immunology portfolio decreased by 3.9% on a reported basis, primarily due to Humira biosimilar competition, with Humira revenues declining by 35.9%.
• Skyrizi and Rinvoq showed strong growth, with revenues increasing by 47.6% and 59.3%, respectively.
• The oncology portfolio saw a 9.0% increase in global net revenues, driven by Venclexta, while Imbruvica revenues decreased by 4.5%.
• The neuroscience portfolio experienced a 15.9% increase in global net revenues, with strong performances from Botox Therapeutic and Vraylar.
• The aesthetics portfolio saw a 4.0% decrease in global net revenues, with declines in both Botox Cosmetic and Juvederm revenues.
• AbbVie successfully completed the acquisition of ImmunoGen, adding Elahere to its oncology portfolio.
• The company raised its 2024 adjusted diluted EPS guidance range from $10.97 $11.17 to $11.13 $11.33.
• Robert A. Michael will succeed Richard A. Gonzalez as CEO, effective July 1, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the raised full-year guidance and strong performance in key growth areas like Skyrizi, Rinvoq, and neuroscience. However, the decline in Humira and aesthetics revenue, along with the decrease in adjusted EPS, tempers the overall positive outlook.

Positives

• AbbVie's total net revenues increased by 0.7% on a reported basis and 1.6% on an operational basis.
• GAAP diluted EPS saw a significant increase of 492.3% to $0.77.
• Skyrizi and Rinvoq demonstrated strong revenue growth, increasing by 47.6% and 59.3%, respectively.
• The neuroscience portfolio experienced a substantial 15.9% increase in revenue.
• The acquisition of ImmunoGen and its flagship cancer therapy, Elahere, was successfully completed.
• AbbVie raised its full-year adjusted diluted EPS guidance, indicating positive future expectations.
• Rinvoq showed positive results in Phase 3 trials for giant cell arteritis and atopic dermatitis.
• The FDA granted full approval for Elahere and priority review for Epkinly.

Negatives

• Adjusted diluted EPS decreased by 6.1% to $2.31.
• The immunology portfolio experienced a 3.9% decrease in revenue due to Humira biosimilar competition.
• Humira revenues declined significantly by 35.9%.
• The aesthetics portfolio saw a 4.0% decrease in revenue.
• Botox Cosmetic and Juvederm revenues decreased by 3.9% and 16.4%, respectively.
• Imbruvica revenues decreased by 4.5%.

Risks

• Continued biosimilar competition for Humira poses a significant risk to revenue.
• The aesthetics portfolio is experiencing a decline in revenue, which could impact overall performance.
• The company faces risks related to the integration of acquired companies, such as ImmunoGen.
• There are risks associated with the development and regulatory approval of new drugs.
• The company is exposed to risks related to changes in laws and regulations applicable to the pharmaceutical industry.
• The company is exposed to risks related to the proposed acquisition of Cerevel Therapeutics, including the possibility that the acquisition may not be consummated.

Future Outlook

AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.97 $11.17 to $11.13 $11.33, which includes an unfavorable impact of $0.08 per share related to acquired IPR&D and milestones expense incurred during the first quarter 2024. The company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of 2024, as both cannot be reliably forecasted.

Management Comments

• Richard A. Gonzalez stated that AbbVie continues to demonstrate outstanding operational execution and delivered another quarter of strong results.
• Richard A. Gonzalez expressed pride in the organization built over the past 11 years.
• Robert A. Michael said that first quarter results were well ahead of expectations, driven by excellent performance from the ex-Humira growth platform.
• Robert A. Michael stated that based on strong results and significant momentum, they are raising the full-year outlook.

Industry Context

The results reflect the ongoing challenges faced by AbbVie due to biosimilar competition for Humira, a major revenue driver. The company is successfully diversifying its portfolio with strong growth in Skyrizi, Rinvoq, and the neuroscience segment. The acquisition of ImmunoGen and the development of new therapies like Elahere and Epkinly are strategic moves to strengthen its pipeline and future growth prospects. The leadership transition is a significant event, but the company is projecting confidence in its future performance.

Comparison to Industry Standards

• AbbVie's performance is mixed compared to industry standards. While the company has shown strong growth in specific areas, the decline in Humira revenue due to biosimilar competition is a significant challenge, similar to what other companies with blockbuster drugs facing generic competition have experienced.
• The growth of Skyrizi and Rinvoq is comparable to other successful launches of new immunology drugs by competitors like Eli Lilly (with Taltz and Olumiant) and Johnson & Johnson (with Tremfya and Stelara).
• The oncology portfolio's growth is in line with the industry trend of increasing focus on targeted therapies and antibody-drug conjugates, with Elahere being a key addition, similar to the strategies of companies like Seagen and Daiichi Sankyo.
• The neuroscience portfolio's growth is strong, reflecting the increasing demand for treatments in this area, similar to the success of companies like Biogen and Teva in the neurology space.
• The aesthetics portfolio's decline is a concern, as this is a competitive market with companies like Galderma and Merz also vying for market share. AbbVie's performance in this segment is below the industry average growth rate.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the raised full-year EPS guidance and the leadership transition.
• Employees will be affected by the leadership change and the ongoing integration of acquired companies.
• Patients will benefit from the development and commercialization of new therapies.
• Customers will be impacted by the performance of AbbVie's products and services.
• Suppliers and creditors will be affected by the company's financial performance and strategic decisions.

Next Steps

• AbbVie will continue to focus on the growth of its ex-Humira portfolio.
• The company will integrate ImmunoGen and Elahere into its oncology business.
• AbbVie will continue to develop and commercialize new therapies in immunology, oncology, neuroscience, and aesthetics.
• The leadership transition will be completed on July 1, 2024.
• AbbVie will host an investor conference call to discuss the first-quarter performance.

Key Dates

Keywords

AbbVie, Financial Results, Q1 2024, Humira, Skyrizi, Rinvoq, Elahere, Immunology, Oncology, Neuroscience, Aesthetics, EPS, Acquisition, Leadership Change